Financial Performance - Operating revenue for the period reached CNY 360,920,838.92, a year-on-year increase of 14.97%[8] - Net profit attributable to shareholders was CNY 73,242,433.68, reflecting a growth of 31.66% compared to the same period last year[8] - Basic earnings per share rose by 31.75% to CNY 0.1390[8] - Total operating revenue for the period reached ¥360,920,838.92, an increase of 14.94% compared to ¥313,939,505.24 in the previous period[61] - Net profit for the period was ¥73,505,397.57, representing a 31.88% increase from ¥55,770,323.44 in the prior period[64] - The company reported a total comprehensive income of ¥74,500,831.87, compared to ¥55,770,323.44, an increase of 33.54%[68] - The company reported a net profit of ¥275,417,504.37 for the current period, up 12.0% from ¥245,813,301.00 in the previous period[81] - The company achieved a profit margin of approximately 9.3% for the current period based on net profit and operating revenue[75] - The net profit for the current period was ¥265,579,490.65, up 30% from ¥204,418,012.77 in the previous period[93] - The total comprehensive income for the current period was ¥265,579,490.65, compared to ¥204,418,012.77 in the previous period, indicating a growth of 30%[93] Assets and Liabilities - Total assets increased by 19.51% to CNY 2,763,884,524.27 compared to the end of the previous year[8] - The company's net assets attributable to shareholders increased by 6.04% to CNY 2,151,827,727.38[8] - Total current assets increased to ¥1,935,999,071.29 as of September 30, 2019, up from ¥1,488,871,156.64 on December 31, 2018, representing a growth of approximately 30%[44] - Total liabilities increased significantly, with short-term borrowings rising to ¥300,000,000.00, marking a 100.00% increase[24] - Total liabilities amounted to ¥595,711,877.63, up from ¥267,538,956.74, which is an increase of approximately 122%[47] - The total liabilities increased to ¥550,686,722.72, compared to ¥354,866,576.20, marking a rise of 55.06%[60] - Total equity reached ¥2,024,924,889.77, up from ¥1,913,843,336.11, indicating a growth of 5.79%[60] - The total assets amounted to $2,268,709,912.31, with non-current assets totaling $878,515,473.11[122] - Current liabilities totaled $316,692,142.27, including accounts payable of $65,010,972.88 and other payables of $220,308,821.61[122] Cash Flow - The net cash flow from operating activities decreased by 35.18% to CNY 63,606,061.25[8] - Cash and cash equivalents increased by 210.10% to ¥1,226,500,059.66 from ¥395,511,523.60 due to the redemption of financial products and new short-term bank loans[24] - The cash flow from operating activities generated a net amount of ¥261,620,183.79, down 35% from ¥403,629,729.41 in the previous period[94] - The total cash and cash equivalents at the end of the period reached 1,024,726,022.03, up from 54,760,145.30 in the previous period, marking a substantial increase[106] - The company reported a total operating cash inflow of 1,164,198,754.41, significantly higher than 690,108,187.90 in the last period, representing an increase of approximately 69%[103] Expenses - Research and development expenses increased by 39.08% to ¥29,638,785.15 from ¥21,310,662.28, reflecting increased investment in new product development[24] - The company reported a 70.56% increase in management expenses, totaling ¥74,628,053.67, primarily due to higher depreciation and employee compensation[24] - Total operating costs amounted to ¥284,127,491.99, up from ¥256,259,889.05, reflecting a growth of 10.85%[61] - Sales expenses surged to ¥24,268,846.94, a significant increase from ¥2,859,834.39, reflecting a rise of 748.5%[72] - The company's management expenses increased to ¥42,997,276.14 from ¥36,623,397.59, representing a rise of 17.5%[86] Shareholder Information - The company reported a total of 15,645 common shareholders at the end of the reporting period[12] - The largest shareholder, Gansu Qizheng Industrial Group Co., Ltd., held 68.76% of the shares[12]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 609,757,574.22, representing a 12.44% increase compared to CNY 542,308,302.55 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 202,076,832.88, up 6.28% from CNY 190,128,060.21 year-on-year[25]. - Basic earnings per share increased by 5.79% to CNY 0.3816 from CNY 0.3607 in the same period last year[25]. - Operating profit reached RMB 224.74 million, up 6.08% compared to the previous year[74]. - The company reported a total of CNY 15,651,831.97 in non-recurring gains and losses during the reporting period[33]. - The weighted average return on net assets was 9.60%, slightly down from 9.78% in the previous year[25]. - The revenue from transdermal patches was RMB 464,692,354.41, accounting for 76.21% of total revenue, with a year-on-year growth of 11.32%[81]. - The gross profit margin for the pharmaceutical industry was 88.06%, with a slight decrease of 0.02% compared to the previous year[78]. Cash Flow and Assets - The net cash flow from operating activities decreased by 44.34%, amounting to CNY 198,014,122.54 compared to CNY 355,738,129.04 in the previous year[25]. - Total assets at the end of the reporting period were CNY 2,521,495,615.08, reflecting a 9.02% increase from CNY 2,312,773,222.44 at the end of the previous year[25]. - The company reported a significant increase in cash and cash equivalents, which rose by 103.98% compared to the beginning of the year[50]. - The accounts receivable increased by 664.09% compared to the beginning of the year, mainly due to the recovery period not being reached according to credit policies[50]. - The total assets at the end of the reporting period were RMB 2,520,000,000, with cash and cash equivalents amounting to RMB 806,778,033.39, representing 32.00% of total assets[84]. Investment and R&D - R&D investment increased by 64.15% to RMB 19.65 million, driven by new product development efforts[74]. - The company has a complete supply, research and development, production, and sales system, enhancing its innovation capabilities in Tibetan medicine[42][44]. - The company plans to focus on enhancing brand and product quality in response to regulatory challenges in the pharmaceutical industry[116]. - The company aims to increase investment in R&D, particularly in new drugs with clear clinical value, and strengthen talent acquisition and training[120]. Marketing and Sales - The company has a marketing team of over 1,000 people, promoting its products through academic and brand promotion models across more than 30 provinces and regions[48]. - The company expanded its pain management product line, focusing on integrated pain relief solutions[60]. - Sales expenses rose by 12.00% to RMB 258.30 million, reflecting increased marketing efforts[74]. Corporate Governance and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[9]. - The company granted 2.266 million restricted stocks to 65 incentive targets as part of the 2019 Restricted Stock Incentive Plan[135]. - The largest shareholder, Gansu Qizheng Industrial Group Co., Ltd., holds 68.77% of the shares, totaling 280,780,000 shares[184]. - The total number of ordinary shareholders at the end of the reporting period was 15,418[182]. - The company has not engaged in any related party transactions during the reporting period[142]. Social Responsibility and Environmental Impact - The company contributed a total of CNY 231.65 million (approximately USD 33.5 million) towards poverty alleviation efforts, including CNY 230.05 million for improving educational resources in impoverished areas[162]. - The company operates a wastewater treatment facility that meets pollution discharge standards, with total emissions of ammonia nitrogen at 0.003 tons and total nitrogen at 0.02 tons[153]. - The company has received certifications for environmental management, including ISO 14001[158]. - The company focused on poverty alleviation projects in Tibet, including educational support for orphans and impoverished students[166]. Challenges and Future Outlook - The company faced challenges due to intensified regulatory scrutiny and slow growth in retail pharmacy channels[116]. - The company has not made any significant changes to the feasibility of its projects during the reporting period[101]. - The company did not report any significant contracts or guarantees during the reporting period[151].

Financial Performance - The company's operating revenue for 2018 was CNY 1,213,209,064.74, representing a 15.20% increase compared to CNY 1,053,150,898.73 in 2017[23] - The net profit attributable to shareholders of the listed company was CNY 318,767,001.93, a 5.96% increase from CNY 300,842,399.36 in the previous year[23] - The net cash flow from operating activities reached CNY 499,396,887.72, showing a significant increase of 117.29% compared to CNY 229,827,826.20 in 2017[23] - The basic earnings per share for 2018 was CNY 0.7851, up 5.95% from CNY 0.7410 in 2017[23] - The total assets at the end of 2018 amounted to CNY 2,312,773,222.44, a slight increase of 0.71% from CNY 2,296,568,381.10 at the end of 2017[23] - The net profit after deducting non-recurring gains and losses was CNY 275,434,568.69, a slight decrease of 0.29% compared to CNY 276,223,716.47 in 2017[23] - The operating profit for the year was 354 million yuan, an increase of 9.98% compared to the previous year[69] - The company achieved a total revenue of 1.213 billion yuan in 2018, representing a year-on-year growth of 15.20%[69] - The company's net profit for the year was reported at 302,900,249.10 yuan, with a remaining distributable profit of 860,101,155.55 yuan after the dividend distribution[171] Dividend Distribution - The company plans to distribute a cash dividend of CNY 4.10 per 10 shares (including tax) and issue 3 bonus shares per 10 shares (including tax) based on a total of 406,000,000 shares[7] - The company distributed cash dividends of 4.10 CNY per 10 shares, totaling 166,460,000 CNY, based on a total share capital of 406,000,000 shares as of the end of 2017[163] - The cash dividend paid in 2018 was 166,460,000 yuan, accounting for 52.22% of the net profit attributable to ordinary shareholders[168] - The cash dividend paid in 2017 was also 166,460,000 yuan, which represented 55.33% of the net profit attributable to ordinary shareholders[168] - The total number of shares for the dividend distribution is based on 406,000,000 shares, with an additional distribution of 3 bonus shares for every 10 shares held[169] Research and Development - The company has a dedicated R&D system aimed at enhancing innovation capabilities, focusing on new drug development and improving quality standards[44] - The company’s R&D efforts are focused on developing high clinical value new products and expanding non-drug product lines, supported by collaborations with top academic institutions[64] - The company is committed to R&D focused on unmet clinical needs, developing new pain relief products, and ensuring sustainable resource management[153] - The company's R&D expenses increased by 42.90% year-on-year, totaling 36,813,975.58 CNY, reflecting a focus on new product development and enhancements[114] - The R&D personnel count decreased by 4.67% to 204, while the R&D investment as a percentage of operating income remained stable at 3.98%[118] Market Position and Strategy - The company has established itself as a leading innovator in Tibetan medicine, focusing on the development of modernized Tibetan pharmaceuticals through advanced research and technology[36] - The company aims to build the first brand for integrated pain solutions, focusing on musculoskeletal pain management with a product lineup that includes pain relief patches and various ointments[59] - The company maintains the leading market share in orthopedic pain relief products, but faces significant competition from similar products, particularly in Western medicine and medical devices[147] - In 2018, the company shifted its development strategy from establishing product advantages to establishing therapeutic domain advantages, focusing on pain relief and expanding into women's health and pediatric fields[148] - For 2019, the company plans to strengthen its core pain relief product line, emphasizing academic marketing and exploring digital marketing for prescription drugs[149] Operational Highlights - The company operates a comprehensive supply chain, integrating direct procurement from farmers and market purchases for raw materials, ensuring quality and cost-effectiveness[43] - The company has a robust sales system with over 1,000 personnel, promoting products through academic and brand marketing strategies across more than 30 provinces[48] - The company has successfully launched new oral pain relief products, enhancing its integrated pain management product line[71] - The company has established wild nurturing bases and artificial planting demonstration bases for key Tibetan medicinal materials, contributing to sustainable resource development[65] - The company has received multiple awards for its pain relief patch, including recognition as the highest recommended brand in the pain relief category by Chinese pharmacies[59] Financial Position and Investments - The total investment cash inflow was 1,588,420,468.11 CNY, a 66.58% increase from the previous year, while the cash outflow for investment activities was 1,683,943,146.99 CNY, up 40.77%[119] - The company has invested CNY 3,720.77 million in excess fundraising, with CNY 3,124.17 million allocated to the Guangzhou marketing center office project[137] - The total amount of funds raised and utilized reached CNY 32,748.51 million, reflecting a substantial increase from CNY 24,874.3 million in the previous period[137] - The company has completed its fundraising projects, with a total of CNY 9,953.71 million used to permanently supplement working capital[138] - The company has established Cheezheng Inc. with a 100% ownership stake during the reporting period, indicating a strategic expansion[109] Compliance and Governance - The company has committed to ensuring that no funds are occupied by controlling shareholders, protecting the interests of minority shareholders[178] - The company has made a commitment to avoid any related party transactions that could harm the interests of minority shareholders[178] - The company has confirmed that all commitments made to minority shareholders have been fulfilled on time[180] - The company has not reported any non-operating fund occupation by controlling shareholders during the reporting period[181] - The company has ensured compliance with the revised financial reporting formats as mandated by the Ministry of Finance[181]

Financial Performance - The company's operating revenue for Q1 2019 was ¥253,751,327.31, representing an increase of 11.78% compared to ¥227,009,592.79 in the same period last year[11]. - The net profit attributable to shareholders for Q1 2019 was ¥84,775,457.81, up by 9.98% from ¥77,080,535.58 in the previous year[11]. - Basic earnings per share for Q1 2019 were ¥0.2088, reflecting a growth of 9.95% from ¥0.1899 in the previous year[11]. - The company reported a net profit for the current period of ¥84,479,612.85, representing a growth of 10% from ¥76,867,042.08 in the previous period[63]. - The net profit for the current period is 57,878,122.53, an increase from 47,599,629.39 in the previous period, representing a growth of approximately 21.4%[71]. - The total comprehensive income for the current period is 57,878,122.53, compared to 47,599,629.39 in the previous period, indicating a year-over-year increase of about 21.4%[73]. Cash Flow - The net cash flow from operating activities was negative at -¥76,654,708.01, a decrease of 171.43% compared to ¥107,313,068.85 in the same period last year[11]. - The cash flow from operating activities shows a net outflow of -76,654,708.01, a significant decrease from a net inflow of 107,313,068.85 in the previous period[77]. - Cash inflow from investment activities is 143,566,945.31, while cash outflow is 313,213,612.95, resulting in a net cash flow from investment activities of -169,646,667.64[80]. - The cash flow from financing activities shows a net inflow of 482,390.00, contrasting with a net outflow of 163,883,014.89 in the previous period[80]. - The company’s cash flow from operating activities remains strong, supporting ongoing investments in new product development and market expansion strategies[60]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,344,447,385.37, an increase of 1.37% from ¥2,312,773,222.44 at the end of the previous year[11]. - Total liabilities increased by 111.49% to ¥18,766,677.12 from ¥8,873,757.85, primarily due to higher payables for raw materials and project payments[27]. - Total liabilities decreased to ¥346,888,940.04 from ¥354,866,576.20, indicating a reduction of approximately 2%[59]. - The total assets and liabilities combined reached ¥2,319,335,007.14, an increase from ¥2,268,709,912.31, showing a growth of 2.2%[59]. - The total cash and cash equivalents at the end of the period is 149,692,537.95, down from 254,125,773.27 at the beginning of the period[80]. Investments and Income - The company reported an investment income of ¥6,817,608.32 from financial products during the reporting period[11]. - Investment income surged by 2133.68% to ¥6,817,608.32 from ¥305,219.18, driven by increased returns from financial products[27]. - The company reported a significant increase in cash paid for purchasing goods and services, totaling $24,341,009.16, compared to $23,693,239.51 previously[83]. Expenses - Research and development expenses rose by 47.26% to ¥5,824,296.60 from ¥3,955,244.77, reflecting increased spending on technology research[27]. - The company reported a 91.40% increase in management expenses to ¥20,807,555.90 from ¥10,871,374.41, driven by higher depreciation, employee compensation, and consulting fees[27]. - The company paid 71,063,631.32 in cash to employees, an increase from 56,852,863.75 in the previous period, representing a growth of about 24.9%[77]. Shareholder Information - The top shareholder, Gansu Qizheng Industrial Group Co., Ltd., holds 69.16% of the shares, totaling 280,780,000 shares[16]. - The company did not engage in any repurchase transactions during the reporting period[21].

西藏奇正藏药股份有限公司 2018 年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 公告编号：2018-067 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2018年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 中国 西藏 2018年10月 1 西藏奇正藏药股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,302,469,448.48 | 2,296,568,381.10 | | 0.26% | | 归属于上市公司股东的净资产 | 1,956,277,846.43 | 1,876,980,582.32 | | 4.22% | | （元） | | | ...

西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2018年半年度报告 证券代码：002287 证券简称：奇正藏药 中国 西藏 2018年08月 西藏奇正藏药股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人雷菊芳、主管会计工作负责人刘凯列及会计机构负责人(会计主管人员)裴庆 红声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展陈述，属于计划性事项，并不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 公司已在本报告中描述了公司可能面临的风险，请查阅本报告第四节之经营情况讨论与 分析中相应内容，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 | 第一节 | 重要提示、目录和释义 1 | | --- | --- | | 第二节 | 公司简介和主要财务指标 4 ...

西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2018年第一季度报告 证券代码：002287 证券简称：奇正藏药 中国 西藏 西藏奇正藏药股份有限公司 2018 年第一季度报告全文 2018年04月 1 西藏奇正藏药股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人雷菊芳、主管会计工作负责人刘凯列及会计机构负责人(会计主 管人员)裴庆红声明：保证季度报告中财务报表的真实、准确、完整。 2 西藏奇正藏药股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 3 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 227,009,592.79 | 193 ...

西藏奇正藏药股份有限公司 2018 年第一季度报告正文 证券代码：002287 证券简称：奇正藏药 公告编号：2018-021 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2018年第一季度报告正文 证券代码：002287 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人雷菊芳、主管会计工作负责人刘凯列及会计机构负责人(会计主 管人员)裴庆红声明：保证季度报告中财务报表的真实、准确、完整。 2 西藏奇正藏药股份有限公司 2018 年第一季度报告正文 证券简称：奇正藏药 中国 西藏 2018年04月 1 西藏奇正藏药股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | -- ...

2017年年度报告 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2018年04月 1 西藏奇正藏药股份有限公司 2017 年年度报告全文 西藏奇正藏药股份有限公司 证券代码：002287 证券简称：奇正藏药 中国 西藏 公司已在本报告中描述了公司可能面临的风险，请查阅本报告第四节之经营情况讨论与 分析中相应内容，敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 406000000 为基数，向全体股东每 10 股派发现金红利 4.10 元（含税），送红股 0 股（含税），不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 5 | | | 第三节 | 公司业务概要 9 | | | 第四节 | 经营情况讨论与分析 | 15 | | 第五节 | 重要事项 | 32 | | 第六节 | 股份变动及股东情况 | 46 | | 第七节 | 优先股相关情况 | 51 | | 第八节 | 董事、监事、高级管理人员和员工情况 | 52 | | 第九节 | 公司治理 ...

西藏奇正藏药股份有限公司 2017 年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 公告编号：2017-049 西藏奇正藏药股份有限公司 Tibet Cheezheng Tibetan Medicine Co.,Ltd 2017年第三季度报告正文 证券代码：002287 证券简称：奇正藏药 中国 西藏 2017年10月 1 西藏奇正藏药股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人雷菊芳、主管会计工作负责人李金明及会计机构负责人(会计主管人员)裴庆 红声明：保证季度报告中财务报表的真实、准确、完整。 2 西藏奇正藏药股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | ...